{"id":"NCT01249261","sponsor":"Warner Chilcott","briefTitle":"Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover","officialTitle":"A 1-year, Risedronate-free, Multicenter, Outpatient, Phase IIIb Extension Study to Assess Bone Turnover Recovery in Women With Postmenopausal Osteoporosis Who Sequentially Completed Clinical Studies RVE009093, RVE1996077, and RVE1998080 (no NCT Study Numbers)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-10","primaryCompletion":"2003-05","completion":"2003-05","firstPosted":"2010-11-29","resultsPosted":"2011-10-26","lastUpdate":"2011-11-02"},"enrollment":61,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Postmenopausal Women With Osteoporosis"],"interventions":[{"type":"DRUG","name":"Risedronate","otherNames":[]},{"type":"DRUG","name":"Placebo/Risedronate","otherNames":[]}],"arms":[{"label":"Placebo/Risedronate","type":"PLACEBO_COMPARATOR"},{"label":"Risedronate","type":"ACTIVE_COMPARATOR"}],"summary":"The effects of stopping long-term (7 years) and short term (2 years) risedronate therapy on BMD (bone mineral density) and BTMs (bone turnover markers) will be summarized.","primaryOutcome":{"measure":"Mean Percent Change in Lumbar Spine Bone Mineral Density (BMD) From Core Study Baseline, Month 6, Intention to Treat (ITT) Population","timeFrame":"Baseline Core Study (Year 1) to Month 6 (Year 8)","effectByArm":[{"arm":"Placebo/Risedronate","deltaMin":6.2217,"sd":1.82459},{"arm":"Risedronate","deltaMin":12.7784,"sd":2.09663}],"pValues":[]},"eligibility":{"minAge":null,"sex":"FEMALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":13,"countries":["Australia","Belgium","Denmark","Finland","Italy","Poland","Spain","Sweden"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":30},"commonTop":["Back Pain","Infection","Accidental Injury","Hypertension","Urinary Tract Infection"]}}